Showing results (361-370 of 389) with videos related to

Sort By:
Pageof 39
The European Respiratory Journal|April 1, 2022
Nintedanib plus chemotherapy for nonsmall cell lung cancer with idiopathic pulmonary fibrosis: a randomised phase 3 trialKohei Otsubo, Junji Kishimoto, Masahiko Ando, et al.
Scientific Reports|November 5, 2025
Diagnostic utility of high-mobility group box 1 for acute exacerbations of idiopathic pulmonary fibrosisNaoki Hamada, Shoji Tokunaga, Toyoshi Yanagihara, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2021
Rovalpituzumab Tesirine as a Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage-SCLC: Results From the Phase 3 MERU StudyMelissa L Johnson, Zanete Zvirbule, Konstantin Laktionov, et al.
BMJ Open Respiratory Research|November 14, 2023
Survival and acute exacerbation for patients with idiopathic pulmonary fibrosis (IPF) or non-IPF idiopathic interstitial pneumonias: 5-year follow-up analysis of a prospective multi-institutional patient registryKazuya Tsubouchi, Naoki Hamada, Shoji Tokunaga, et al.
Respirology (Carlton, Vic.)|July 8, 2026
Clinical Outcomes and Acute Exacerbation Incidence in Combined Pulmonary Fibrosis and EmphysemaKazuya Tsubouchi, Yasuaki Kotetsu, Tomotsugu Takano, et al.
Lung Cancer (Amsterdam, Netherlands)|June 26, 2026
Durvalumab plus etoposide-platinum in patients with epidermal growth factor receptor (EGFR)-mutated advanced NSCLC and neuroendocrine transformation after first-line osimertinib: ORCHARDIsamu Okamoto, Byoung Chul Cho, Sarah B Goldberg, et al.
Clinical Lung Cancer|August 14, 2021
Biomarker-Directed Phase II Platform Study in Patients With EGFR Sensitizing Mutation-Positive Advanced/Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy (ORCHARD)Helena A Yu, Sarah B Goldberg, Xiuning Le, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 19, 2021
Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE StudyFiona Blackhall, Kevin Jao, Laurent Greillier, et al.
Cancer Letters|December 26, 2024
TIM3 on natural killer cells regulates antibody-dependent cellular cytotoxicity in HER2-positive gastric cancerChikanori Tsutsumi, Kenoki Ohuchida, Hirono Tsutsumi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2019
Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non-Small Cell Lung CancerJhanelle E Gray, Isamu Okamoto, Virote Sriuranpong, et al.
Pageof 39